Brief: Pfizer Says LB6V Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified At Time Of Analysis
23/03/2026 10:45
March 23 (Reuters) - Pfizer Inc PFE.N: PFIZER: LB6V VACCINE CANDIDATE WAS WELL TOLERATED WITH NO SAFETY CONCERNS IDENTIFIED AT TIME OF ANALYSIS PFIZER: CO & VALNEVA ANNOUNCE LYME DISEASE VACCINE CANDIDATE DEMONSTRATES STRONG EFFICACY IN PHASE 3 VALOR TRIAL PFIZER: PLANNING SUBMISSIONS FOR LB6V VACCINE CANDIDATE TO REGULATORY AUTHORITIES PFIZER: VACCINE CANDIDATE LB6V SHOWED MORE THAN 70% EFFICACY IN PREVENTING LYME DISEASE IN PEOPLE AGED FIVE YEARS & ABOVE Source text: [ID:] Further company coverage: PFE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency